Publications by authors named "Andrea Picci"
A case of LIMA side branch coronary steal syndrome: a role for embolization.
Catheter Cardiovasc Interv
November 2024
Article Synopsis
- Failure to properly close side branches of the internal mammary artery during bypass surgery can lead to ischemia because of a condition called coronary steal.
- A 56-year-old man experienced recurring chest pain after heart surgery, leading to further examination.
- The patient underwent a successful procedure to block the problematic branch, which resulted in improved blood flow and alleviated his symptoms.
Background: Cardiogenic Shock (CS) complicating acute myocardial infarction (AMI) poses a significant mortality risk, suggesting the opportunity to implement effective mechanical circulatory support strategies. The comparative efficacy of Intra-Aortic Balloon Pump (IABP) and Impella in managing CS-AMI remains a subject of investigation.
Objective: This meta-analysis aims to evaluate the comparative effectiveness of Impella and IABP in managing CS-AMI, exploring mortality and adverse events.
Background: Women present specific risks for transcatheter aortic valve replacement (TAVI) but there are scarce sex-based analysis. The aim of this study was to explore the risk of vascular/bleeding complications in females vs. males that underwent TAVI and the impact of red blood cell (RBC) transfusion.
View Article and Find Full Text PDFArticle Synopsis
- Vascular complications are a significant concern after transcatheter aortic valve implantation (TAVI), prompting researchers to explore ways to improve patient outcomes.
- This study assessed the effectiveness of using an Angio-Seal (AS) device alongside suture-based devices (SBDs) for improving endovascular closure after transfemoral TAVI, focusing on major complications and bleeding rates.
- Results showed that patients receiving the combined AS and SBD treatment had significantly lower rates of major bleeding and vascular complications, along with cost savings and a greater likelihood of being discharged the next day, without affecting overall mortality rates.
Aortic stenosis (AS) is one of the most common valvular diseases in developed countries. Transcatheter aortic valve implantation (TAVI) has emerged as alternative to medical treatment or surgical aortic valve replacement (SAVR) in all symptomatic patients with severe AS. In 2002, Cribier performed the first human TAVI through a trans-septal approach in a 57-year-old man with severe AS.
View Article and Find Full Text PDFCoronary Cannulation After Transcatheter Aortic Valve Replacement: The RE-ACCESS Study.
JACC Cardiovasc Interv
November 2020
Objectives: The aims of this study were to investigate the feasibility of coronary ostia cannulation after transcatheter aortic valve replacement (TAVR) and to assess potential predictors of coronary access impairment.
Background: Certain data concerning the feasibility and reproducibility of coronary cannulation after TAVR are lacking.
Methods: RE-ACCESS (Reobtain Coronary Ostia Cannulation Beyond Transcatheter Aortic Valve Stent) was an investigator-driven, single-center, prospective, registry-based study that enrolled consecutive patients undergoing TAVR using all commercially available devices.
Article Synopsis
- The study aimed to assess the predictors and safety of next-day discharge (NDD) after transfemoral transcatheter aortic valve implantation (TF-TAVI) in patients using either balloon-expandable or self-expanding devices.
- Conducted from 2007 to 2018, the study involved 1,232 patients averaging 80.9 years, with 13% discharged within 24 hours; there were no significant differences in mortality or complications between those discharged early and later.
- Prior permanent pacemaker implantation and preprocedural computed tomography angiography were identified as predictors of NDD, suggesting that this discharge strategy is safe for patients without major complications.
Objectives: The aim of this study was to evaluate and compare the outcomes of transcatheter self-expandable prostheses in patients with small annuli.
Background: Transcatheter aortic heart valves appear to have better performance than surgical valves in terms of prosthesis-patient mismatch, especially in patients with aortic stenosis with small aortic annuli.
Methods: TAVI-SMALL (International Multicenter Registry to Evaluate the Performance of Self-Expandable Valves in Small Aortic Annuli) is a retrospective registry of patients with severe aortic stenosis and small annuli (annular perimeter <72 mm or area <400 mm on computed tomography) treated with transcatheter self-expandable valves (n = 859; Evolut R, n = 397; Evolut PRO, n = 84; ACURATE, n = 201; Portico, n = 177).
Outcomes of three different new generation transcatheter aortic valve prostheses.
Catheter Cardiovasc Interv
February 2020
Article Synopsis
- The study aims to assess the outcomes of three new-generation transcatheter aortic valve devices used in patients with severe aortic stenosis undergoing transfemoral implantation.
- Conducted between 2014 and 2018, the study involved 346 patients and utilized a propensity score weighting method to account for differences in clinical characteristics among the three devices (Edwards SAPIEN 3, Medtronic Evolut R, and Boston ACURATE neo).
- Results showed no difference in 30-day mortality rates or one-year outcomes, but the Evolut R device had a higher risk of requiring permanent pacemaker implantation, while the SAPIEN 3 valve had better performance in terms of transvalvular gradient and lower
Aims: The aims of this study were to determine the appropriateness of permanent pacemaker implantation (PPI) after TAVI through an analysis of PM dependency at follow-up, and to assess long-term outcomes of patients undergoing PPI after TAVI.
Methods And Results: From June 2007 to February 2018, 1,116 consecutive patients without prior PM underwent TAVI in our institution. We assessed the incidence and predictors of PM dependency of patients who underwent PPI within 30 days, and also the six-year outcomes among patients who did not undergo PPI at 30 days.
Background Long-term data on durability of currently available transcatheter heart valves are sparse. We sought to assess the incidence of long-term (8-year) structural valve dysfunction and bioprosthetic valve failure in a cohort of patients with transcatheter aortic valve replacement ( TAVR ) who reached at least 5-year follow-up. Methods and Results Consecutive patients with at least 5-year follow-up available undergoing TAVR from June 4, 2007 to March 30, 2012 were included.
View Article and Find Full Text PDFBackground: We sought to describe an optimized approach to coronary artery disease (CAD) screening and management in patients undergoing transcatheter aortic valve replacement (TAVR).
Methods And Results: When invasive coronary angiography showed CAD, the treatment strategy and completeness of revascularization was determined based on coronary anatomy. TAVR was performed in the same setting if percutaneous coronary intervention (PCI) was uncomplicated; otherwise TAVR was postponed.
Objective: The aim of this study was to conduct a weighted meta-analysis to determine the rates of acute (≤30days) major outcomes after (TAVR) with second-generation devices.
Methods: A comprehensive search of multiple electronic databases from January 2011 to May 2017 was conducted using predefined criteria. New-generation TAVR devices were defined as any device which received CE mark approval or is still under evaluation for CE marking after CoreValve and SAPIEN XT prostheses.
Acute Kidney Injury With the RenalGuard System in Patients Undergoing Transcatheter Aortic Valve Replacement: The PROTECT-TAVI Trial (PROphylactic effecT of furosEmide-induCed diuresis with matched isotonic intravenous hydraTion in Transcatheter Aortic Valve Implantation).
JACC Cardiovasc Interv
October 2015
Objectives: The purpose of this study was to investigate the effect of the RenalGuard System (PLC Medical Systems, Milford, Massachusetts) on prevention of acute kidney injury (AKI) in patients undergoing transcatheter aortic valve replacement (TAVR).
Background: TAVR is associated with varying degrees of post-procedural AKI. The RenalGuard System is a dedicated device designed for contrast-induced AKI prevention.